Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study

Journal of the American Academy of Dermatology

Volumn 50, Issue 4, 2004, Pages 533-540

  Ehrlich, Alison ^a,b   Booher, Susan ^a,b   Becerra, Yvonne ^a,b   Borris, Debra L ^a,b   Figg, W Douglas ^a,b   Turner, Maria L ^a,b   Blauvelt, Andrew ^a,b  

^a National Cancer Institute ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; ETRETINATE; INHIBIN B; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PAXEED; RECOMBINANT INTERLEUKIN 10; RETINOID; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; GONADAL DISEASE; HUMAN; MALE; MICELLIZATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PUVA; SUPRAVENTRICULAR TACHYCARDIA;

EID: 1642291355     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.09.018     Document Type: Article

References (28)

1. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
2. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
4. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003;120:476-82.
5. Hui A, Min WX, Tang J, Cruz TF. Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes. Arthritis Rheum 1998;41:869-76.
6. Wiles ME, Dykens JA, Wright CD. Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J Leukoc Biol 1994;56:192-9.
7. Tange S, Scherer MN, Graeb C, Weiss T, Justl M, Frank E, et al. The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 2002;73:216-23.
8. Chuang LT, Lotzova E, Heath J, Cook KR, Munkarah A, Morris M, et al. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res 1994;54:1286-91.
9. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
10. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6.
11. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46: 1-23.
12. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002; 23:205-8.
13. Grosen E, Siitari E, Larrison E, Tiggelaar C, Roecker E. Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000;355:288-9.
14. Schrump DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. J Thorac Cardiovasc Surg 2002;123:686-94.
15. Illingworth PJ, Groome NP, Byrd W, Rainey WE, McNeilly AS, Mather JP, et al. Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 1996;81:1321-5.
16. Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, et al. IDN 5390: an oral taxane candidate for protracted treatment schedules. Br J Cancer 2003;88:965-72.
17. Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 2000;60:842-6.
18. Rose WC, Lee FY, Golik J, Kadow J. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative. Cancer Chemother Pharmacol 2000;46:246-50.
19. Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7:2016-21.
20. Brahn E, Tang C, Banquerigo ML. Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum 1994;37:839-45.
21. Hui A, Kulkarni GV, Hunter WL, McCulloch CA, Cruz TF. Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Arthritis Rheum 1997;40:1073-84.
22. Arsenault AL, Lhotak S, Hunter WL, Banquerigo ML, Brahn E. Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization. Clin Immunol Immunopathol 1998;86:280-9.
23. Yoo WH, Baek HS. Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma. J Rheumatol 2000; 27:1572-3.
24. Kurose A, Yoshida W, Yoshida M, Sawai T. Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis. Cytometry 2001;44:349-54.
25. Cao L, Sun D, Cruz T, Moscarello MA, Ludwin SK, Whitaker JN. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J Neuroimmunol 2000;108:103-11.
26. Moscarello MA, Mak B, Nguyen TA, Wood DD, Mastronardi F, Ludwin SK. Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Mult Scler 2002;8:130-8.
27. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
28. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003;107:517-20.